Somatropin: What It Is, How It Works & How It Compares to GH Peptides
If you have searched for somatropin, you have probably already run into three or four other words that seem to mean the same thing — somatotropin, HGH, rhGH, 191aa — plus a wall of brand names. This guide untangles the vocabulary, explains what somatropin actually does inside the body, covers what it is and is not approved to treat, and shows where growth hormone peptides fit into the same conversation.
What somatropin actually is
Somatropin is the international non-proprietary name for recombinant human growth hormone — a laboratory-manufactured copy of the growth hormone your own pituitary gland produces. It is a single chain of 191 amino acids, folded and held together by two internal disulfide bonds, and it is structurally identical to the dominant form of growth hormone circulating in a healthy human body.
It is made using recombinant DNA technology, usually in E. coli or mammalian cell systems, and supplied either as a freeze-dried powder or a ready-to-use liquid for subcutaneous injection. Several manufacturers produce it, which is why one molecule carries so many names on the shelf.
The naming decoder
This is where most confusion starts, so it is worth setting out plainly:
| Term | What it actually refers to |
|---|---|
| Somatotropin | The growth hormone your body makes naturally. The endogenous version. |
| Somatropin | The manufactured, recombinant version of that same hormone. The drug name. |
| HGH / hGH | Everyday shorthand for human growth hormone. Used loosely for both the natural and manufactured forms. |
| rhGH | Recombinant human growth hormone. Technically interchangeable with somatropin. |
| 191aa | A reference to the 191-amino-acid chain length, which distinguishes it from older 192-amino-acid preparations. |
| Brand names | Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton, Serostim, Zorbtive. Same active molecule, different manufacturers, devices and licensed uses. |
So somatropin and HGH are not two different things. Somatropin is simply the precise pharmaceutical term for the version made in a lab.
How somatropin works in the body
Growth hormone does not do most of its work directly. It works largely by telling the liver to produce something else.
Once injected, somatropin travels to target tissues and binds the growth hormone receptor, a class I cytokine receptor found on liver, muscle, bone and fat cells. Binding causes the receptor to pair up, which activates an enzyme called JAK2. JAK2 then switches on STAT5 proteins, which travel into the cell nucleus and turn on specific genes.
The most important gene in that group codes for insulin-like growth factor 1 (IGF-1). Circulating IGF-1, produced mainly by the liver, is what carries out much of growth hormone's anabolic signalling — including stimulating the cartilage cells at the growth plates of a child's bones, which is how height increases.
Alongside that indirect route, somatropin has direct effects of its own. It promotes lipolysis, the breakdown of stored fat. It encourages tissues to take up amino acids. And it acts as an insulin antagonist, which is why it reduces insulin sensitivity and can push blood glucose upward — an effect that matters a great deal in the safety discussion further down.
The growth hormone axis. Somatropin enters downstream of the pituitary; growth hormone peptides act upstream of it.
The anti-ageing question, honestly answered
The enthusiasm traces back to one small study. In 1990, a paper in the New England Journal of Medicine reported that 12 men over 60 who received growth hormone three times a week for six months showed statistically significant increases in lean body mass and bone mineral compared with nine untreated men. The finding was real. The interpretation that followed was not proportionate to it.
An entire industry of anti-ageing clinics and an illicit supply chain emerged through the 1990s on the strength of that result and others like it.
The most rigorous assessment came in 2007, when researchers at Stanford published a systematic review in the Annals of Internal Medicine pooling 18 randomised controlled trials of growth hormone in healthy older adults — average age 68, average BMI 27, with anyone who had diabetes, cardiac disease, thyroid disease, osteoporosis or cancer excluded. Their conclusion was that growth hormone in this population produced small changes in body composition alongside increased rates of adverse events, and on that evidence could not be recommended as an anti-ageing therapy.
Later reviews have not overturned it. A 2004 review of interventions for sarcopenia and muscle weakness in older adults found that growth hormone carried a high incidence of side effects and did not increase strength, and that resistance training remained the most effective intervention for building muscle mass and strength in this group. Longer-term outcomes that would actually settle the question — falls, fractures, functional status, cardiovascular events, mortality — have largely not been studied, which is an absence of information rather than a demonstration of safety.
There is also a genuinely uncomfortable counter-signal worth knowing about: animal models of congenital growth hormone deficiency show markedly increased lifespan, and humans with congenital growth hormone deficiency appear to have lower rates of some age-related diseases. The relationship between growth signalling and longevity is not simple, and it does not run in the direction the marketing suggests.
The short version
- For diagnosed growth hormone deficiency, somatropin is well-evidenced replacement therapy.
- For healthy adults seeking anti-ageing effects, the controlled evidence shows small body-composition changes and more side effects.
- Long-term outcome data in healthy adults is thin, not reassuring.
Side effects and safety
Most of somatropin's common side effects trace back to two mechanisms: fluid retention and insulin antagonism.
Fluid-related effects are the most frequently reported, and are notably more common in adults than children. They include peripheral oedema and other swelling, joint pain, muscle pain, and nerve compression symptoms such as paraesthesia and carpal tunnel syndrome. In clinical trials these were generally mild and transient, and they typically respond to a dose reduction.
Metabolic effects include glucose intolerance, impaired fasting glucose, rising insulin levels and insulin resistance. Post-marketing reports include worsening of pre-existing diabetes. This is the effect that makes unsupervised use genuinely risky, because nobody is checking the numbers.
Other documented reactions include headache, injection site reactions and lipoatrophy, benign intracranial hypertension with headache and visual changes, and unmasking of previously undiagnosed central hypothyroidism or hypoadrenalism. Product labelling also carries warnings covering increased mortality in patients with acute critical illness, fatalities in children with Prader-Willi syndrome, neoplasms, and — added to labelling as recently as late 2025 — slipped capital femoral epiphysis in paediatric patients.
Somatropin is contraindicated in acute critical illness, active malignancy and known hypersensitivity to the drug or its excipients.
It is also worth noting that regulators flagged a safety review after a French study reported increased mortality among adults who had been treated with growth hormone as children, particularly where doses exceeded standard levels. Regulators have maintained that benefits outweigh risks at labelled doses and indications, which is exactly the point: the safety record belongs to supervised, correctly dosed, correctly indicated use.
What changed recently: weekly instead of daily
For four decades, growth hormone therapy meant a daily injection. That has changed, and it is the most significant recent development in this field.
Three long-acting growth hormones are now available. Skytrofa (lonapegsomatropin) is a prodrug that releases unmodified somatropin. Sogroya (somapacitan) and Ngenla (somatrogon) are molecularly distinct analogues engineered for extended action. All three are given once weekly.
Ngenla was approved in the United States in June 2023 for children aged three and over with growth failure from inadequate growth hormone secretion. Sogroya expanded significantly on 27 February 2026, when the FDA approved three additional paediatric indications — idiopathic short stature, small for gestational age without catch-up growth by age two, and growth failure associated with Noonan syndrome — in children aged 2.5 and older, on top of its existing approvals for paediatric and adult growth hormone deficiency. A further application covering Turner syndrome is under review.
The trial data behind these approvals was built on non-inferiority: the weekly products had to match daily somatropin on annualised height velocity, not beat it. A network meta-analysis comparing the three found that only lonapegsomatropin was associated with better growth outcomes than daily somatropin, with no significant differences in serious adverse events across the group. The real advantage is adherence — 52 injections a year instead of 365.
Somatropin versus growth hormone peptides
This is where most people searching for somatropin eventually end up, because the two categories get discussed together and the distinction is rarely made clearly.
Somatropin replaces growth hormone. Growth hormone peptides signal the pituitary to release more of its own. The difference is not cosmetic — it changes the shape of the hormone curve, and it changes what happens to the body's feedback system.
Your pituitary does not release growth hormone in a steady stream. It releases it in pulses, concentrated heavily during deep sleep. Injected somatropin bypasses that rhythm and produces a flatter, non-physiological hormone profile, and because the resulting IGF-1 feeds back to suppress the pituitary, it dampens your own production while you are on it.
Growth hormone secretagogues work through the pituitary rather than around it, which means the body's IGF-1 and somatostatin feedback loops stay intact. In practice, that puts a natural ceiling on how high hormone levels can climb — a limitation and a safety feature at the same time.
They fall into two receptor families, and this is why they are often studied in combination:
- GHRH receptor agonists — sermorelin, tesamorelin and CJC-1295 act on the same pituitary receptor your body's own growth hormone-releasing hormone uses.
- Ghrelin receptor agonists — ipamorelin works through a separate and complementary pathway.
Because the two pathways are independent, pairing a GHRH analogue with a ghrelin receptor agonist produces a larger combined response than either produces alone. That is the reasoning behind combination formulations such as CJC-1295 without DAC with ipamorelin.
| Somatropin (rhGH) | GH peptides / secretagogues | |
|---|---|---|
| What it is | The 191-amino-acid hormone itself | Short peptides that signal its release |
| Where it acts | Growth hormone receptors on liver, muscle, bone, fat | GHRH or ghrelin receptors on the pituitary |
| Hormone pattern | Flat, non-pulsatile | Preserves natural pulsatile release |
| Feedback loop | Bypassed; own production suppressed | Intact; IGF-1 and somatostatin still regulate |
| Ceiling on levels | Dose-dependent, no natural limit | Limited by pituitary capacity |
| Regulatory status | Prescription drug with approved indications | Mostly research compounds; tesamorelin is FDA-approved for HIV-associated lipodystrophy |
None of this makes peptides automatically safer or better. It makes them different, with a different mechanism, a different evidence base and different limitations. A secretagogue cannot help someone whose pituitary cannot produce growth hormone in the first place — in true deficiency, replacement is the mechanism that works.
Why sourcing and verification matter here
Growth hormone has a large illicit market, and that market has documented quality problems.
Analytical work from doping control laboratories has turned up a modified growth hormone in black market products consisting of 192 amino acids rather than 191, carrying an extra alanine at one end of the chain. The same body of work has identified altered versions of growth hormone-releasing peptides circulating alongside them. Separately, a systematic review of more than 5,000 anabolic samples seized from the black market found that roughly a third were counterfeit and a further third were substandard — containing no active ingredient, the wrong ingredient, or a different quantity than the label claimed. Those figures cover anabolic steroids rather than growth hormone specifically, but they describe the same unregulated supply chain.
The practical takeaway is straightforward: with compounds in this category, a certificate of analysis from an independent laboratory is not a marketing flourish. It is the only thing standing between a stated identity and purity and an unverified assumption. You can review our COA database for third-party testing on our catalogue.
Explore the growth hormone category
Browse our research-grade growth hormone and secretagogue compounds, each supplied with third-party laboratory testing and handled under controlled cold-chain conditions.
View HGH & GH peptidesFrequently asked questions
Is somatropin the same as HGH?
Essentially yes. HGH is the everyday term for human growth hormone. Somatropin is the pharmaceutical name for the recombinant, laboratory-manufactured version of that same 191-amino-acid molecule. Somatotropin refers to the hormone your body produces on its own.
Do you need a prescription for somatropin?
Yes. Somatropin is a prescription medicine everywhere it is licensed. In the United States, distributing it for purposes outside its approved indications — including anti-ageing and athletic performance — is a federal offence under legislation passed in 1990 specifically to address that market. Requirements differ by country, so check the rules where you are.
How long does somatropin take to work?
It depends entirely on what is being measured. IGF-1 rises within days. Body composition changes take months. In children treated for growth failure, the primary outcome in clinical trials is annualised height velocity measured at 52 weeks — a full year. Nothing about this molecule works quickly.
Are GH peptides a substitute for somatropin?
No. They work by a different mechanism, and they depend on a pituitary that can still produce growth hormone. In diagnosed growth hormone deficiency, secretagogues cannot replicate what replacement therapy does. The categories overlap in what they influence but are not interchangeable.
Why do the newer growth hormones only need weekly injections?
They are engineered to persist longer in circulation. Lonapegsomatropin is a prodrug that slowly releases ordinary somatropin, while somapacitan and somatrogon are structurally modified analogues designed to clear more slowly. Trials measured them against daily somatropin on a non-inferiority basis, so the aim was matching outcomes with fewer injections rather than improving on them.
The bottom line
Somatropin is a serious, well-characterised medicine with a strong evidence base for a narrow list of conditions — and a reputation, built largely outside that evidence base, for things it has not been shown to do well in healthy adults. Understanding which of those two somatropins you are reading about at any given moment is most of the work.
If you want to go deeper on how individual growth hormone peptides differ from one another, our Info Center covers each compound in detail, and the anti-ageing and muscle growth category pages group them by research application.
Sources
- U.S. Food and Drug Administration — Humatrope (somatropin) prescribing information, 2025 label revision.
- U.S. Food and Drug Administration — Norditropin (somatropin) prescribing information.
- U.S. Food and Drug Administration — Drug Safety Communication: ongoing safety review of recombinant human growth hormone (somatropin).
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007;146(2):104–115.
- Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
- Growth Hormone and Aging. Endotext, National Center for Biotechnology Information.
- Novo Nordisk — FDA approval of once-weekly Sogroya (somapacitan-beco) for three additional paediatric indications, 27 February 2026.
- Pfizer and OPKO Health — FDA approval of NGENLA (somatrogon-ghla), June 2023.
- Long-acting growth hormone for paediatric growth hormone deficiency: systematic literature review and network meta-analysis. PMC11938432.
- Stanley TL, Grinspoon SK, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. Study protocol documentation, ClinicalTrials.gov.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45–53.
- Thevis M, et al. Analysis of new growth promoting black market products. Drug Testing and Analysis.
- Fake anabolic androgenic steroids on the black market: a systematic review and meta-analysis. PMC9288681.
- Drugs.com — Somatropin side effects, common, severe and long term.
